undamentalytics Newsletter
Sign in

Relay Therapeutics, Inc. insider trading

Every open-market purchase and sale by Relay Therapeutics, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $0 0 trades by 0 insiders Insider sales, 5 years $130M 40 trades by 5 insiders 3 months later: median +26.1% (+20.4% vs S&P 500)

No insider has bought shares on the open market in five years.

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.
DateInsiderTrade SharesPriceValue 1M after 3M after 6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Relay Therapeutics, Inc.’s insiders pay?

From January 14, 2021 to October 30, 2026, 8 insiders reported 0 open-market purchases and 75 sales not made under a pre-set plan in Relay Therapeutics, Inc. After sales, the shares moved −58.9% against the index over 12 months (a negative figure means selling was the right call).

InsiderRolePurchases12 months after their purchasesBeat the S&P 500Sales12 months after their salesLatest report
Bergstrom Donald A President, R&D 0 — — 25 −55.1% (17) October 30, 2026
Catinazzo Thomas Chief Financial Officer 0 — — 17 −59.7% (11) October 30, 2026
Adams Brian Chief Legal Officer 0 — — 14 −61.0% (11) July 30, 2025
Rahmer Peter See remarks 0 — — 11 −69.3% (3) October 30, 2026
Patel Sanjiv President and CEO 0 — — 5 — January 7, 2026
Porter Andy Chief Administrative Officer 0 — — 1 −53.7% (1) May 2, 2022
Sb Investment Advisers (uk) Ltd 10% owner 0 — — 1 — August 28, 2026
Tepper Robert I 10% owner 0 — — 1 −66.7% (1) January 14, 2021

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Relay Therapeutics, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Relay Therapeutics, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After 6 selling crowds, −29.0%. One company's history is too short to judge by; the test across every company is the better guide.

MonthCrowd3 months on, vs S&P 5006 months12 months
May 29, 20263 selling+31.6%not yetnot yet
February 29, 20244 selling−40.3%−43.1%−83.2%
August 31, 20234 selling−24.3%−15.3%−61.0%
February 28, 20234 selling−38.7%−48.1%−68.1%
November 30, 20223 selling−7.4%−44.1%−67.6%
May 31, 20224 selling+37.9%+15.7%−35.9%
July 30, 20213 selling−3.2%−39.0%−39.3%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Relay Therapeutics, Inc. · Funds · Politicians